Suppr超能文献

变应原特异性免疫治疗中的免疫机制。

Immunological mechanisms operative in allergen-specific immunotherapy.

作者信息

Ebner C

机构信息

Institute of General and Experimental Pathology, University of Vienna, Austria.

出版信息

Int Arch Allergy Immunol. 1999 May;119(1):1-5. doi: 10.1159/000024168.

Abstract

Specific immunotherapy (SIT) is the practice of administering increasing doses of allergen extracts to selected subjects suffering from IgE-mediated hypersensitivity, with the ultimate aim of ameliorating the symptoms associated with exposure to the causative allergen. The process is often called hyposensitization or desensitization because one consequence of the treatment is a reduction in sensitivity of the target organ after challenge with the relevant allergen. SIT has been practiced as treatment of type I allergy caused by inhalant allergens and Hymenoptera venoms for more than 80 years on an empirical basis. Today, numerous double-blind, placebo-controlled studies prove the therapeutic effect of SIT. However, the immunological mechanisms underlying successful specific immunotherapy have still not been completely elucidated. This review focuses on recent attempts to characterize the immunological events associated with SIT.

摘要

特异性免疫疗法(SIT)是指对患有IgE介导的超敏反应的特定受试者给予递增剂量变应原提取物的治疗方法,其最终目的是减轻与接触致病变应原相关的症状。该过程通常被称为减敏或脱敏,因为治疗的一个结果是在使用相关变应原激发后靶器官的敏感性降低。基于经验,SIT作为由吸入性变应原和膜翅目毒液引起的I型过敏的治疗方法已有80多年的历史。如今,大量双盲、安慰剂对照研究证明了SIT的治疗效果。然而,成功的特异性免疫疗法背后的免疫机制仍未完全阐明。本综述重点关注近期对与SIT相关的免疫事件进行特征描述的尝试。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验